Search clinical trials for: stage II melanoma

Total 41472 results

National Cancer Institute (NCI)

Completed

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Ovarian Carcinoma | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Skin Melanoma | Recurrent Non-Small Cell... and other conditions

Canada
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Acral Lentiginous Malignant Melanoma

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Philogen S.p.A.

Completed

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Malignant Melanoma

Austria, Germany
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University Hospital Tuebingen

Completed

NAM-Trial: Multiferon in Malignant Melanoma

Locoregional Metastases in Malignant Melanoma Stages IIIB/C

Germany
Bristol-Myers Squibb
Medarex

Completed

Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma

Melanoma

United States, Brazil, France, Italy, South Africa, United Kingdom, Argentina, Australia, Canada, Ireland, Israel, Russian Federation, Spain, Belgium, Germany, Portugal, Chile, Austria, Poland, Netherlands, Ukraine, Czech Republic, ... and more
Bayer
Amgen

Completed

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States, Canada, Germany, France, United Kingdom, Australia, Netherlands
National Cancer Institute (NCI)

Completed

Lovastatin in Treating Patients At High Risk of Melanoma

Precancerous Condition | Stage II Melanoma | Stage 0 Melanoma | Stage I Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Been Completely Removed by Surgery

Melanoma (Skin)

United States
Herlev Hospital

Completed

Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma

Malignant Melanoma With Metastasis

Denmark
National Cancer Institute (NCI)

Terminated

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
James Graham Brown Cancer Center
University of Louisville

Completed

Phase II Trial of Ontak With Metastatic Melanoma

Malignant Melanoma

United States
Provectus Pharmaceuticals

Completed

Phase 2 Study of Intralesional PV-10 for Metastatic Melanoma

Melanoma

United States, Australia
Yale University
National Cancer Institute (NCI)

Terminated

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Kidney Cancer | Head and Neck Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Intraocular Melanoma | Melanoma (Skin) | Pheochromocytoma | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome | Neuroendocrine Carcinoma of the Skin | Childhood Langerhans Cell Histiocytosis

United States
National Cancer Institute (NCI)

Terminated

Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California

Completed

Novel Adjuvants for Peptide-Based Melanoma Vaccines

Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Melanoma (Skin)

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditions

United States
National Cancer Institute (NCI)

Completed

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Recurrent Melanoma | Stage IV Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA Melanoma

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Intraocular Melanoma | Melanoma (Skin)

United States
California Cancer Assocaties for Research & Excellence

Unknown

Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma

Metastatic Melanoma | Malignant Melanoma of Skin Stage III

United States
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
Bart Neyns

Completed

A Study on the Safety and Immunogenicity of Combined Intradermal and Intravenous Administration of an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Melanoma

Belgium
National Cancer Institute (NCI)

Completed

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Melanoma | Recurrent Melanoma | Stage IV Melanoma | Stage III Melanoma

United States
INSYS Therapeutics Inc
National Cancer Institute (NCI)

Completed

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Cancer

United States
Synta Pharmaceuticals Corp.

Terminated

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Melanoma

United States, Spain, Canada, Australia, Germany, Puerto Rico, Romania, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Completed

Dendritic Cell Vaccination During Lymphoid Reconstruction

Intraocular Melanoma | Melanoma (Skin)

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Completed

Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis

Melanoma (Skin)

United States
San Diego Pacific Oncology & Hematology Associates

Unknown

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

Melanoma (Skin)

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
National Cancer Institute (NCI)

Unknown

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
San Diego Pacific Oncology & Hematology Associates

Unknown

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

Intraocular Melanoma

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

Melanoma (Skin)

United States
Genta Incorporated

Completed

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

Melanoma (Skin)

United States
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States
Genzyme, a Sanofi Company

Unknown

Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma

Melanoma (Skin)

United States
Institute of Cancer Research, United Kingdom

Completed

Interferon Alfa or No Further Therapy Following Surgery in Treating Patients With Stage II, Stage III, or Recurrent Melanoma

Melanoma (Skin)

United Kingdom
CancerVax Corporation

Unknown

Vaccine Therapy in Treating Patients With Malignant Melanoma

Melanoma (Skin)

United States, Australia
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Melanoma (Skin)

United States
University of Virginia
National Cancer Institute (NCI)

Suspended

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Melanoma (Skin)

United States
QLT Inc.

Completed

Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma

Melanoma (Skin)

United States

Search clinical trials for: stage II melanoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations